Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Both sides next revision
pharmaceutical_companies:shanghai_zerun_biotechnology [2022/11/01 04:39]
liam
pharmaceutical_companies:shanghai_zerun_biotechnology [2024/11/17 20:12] (current)
liam [Research and development]
Line 15: Line 15:
   * May 2020: $1,000,000 to support research and development for [[:COVID-19]] response((//Shanghai Zerun Biotechnology Co., Ltd.// (2020, May). Bill & Melinda Gates Foundation. https://archive.ph/yNHyg))   * May 2020: $1,000,000 to support research and development for [[:COVID-19]] response((//Shanghai Zerun Biotechnology Co., Ltd.// (2020, May). Bill & Melinda Gates Foundation. https://archive.ph/yNHyg))
  
-In July 2021, the [[Coalition for Epidemic Preparedness Innovations]] (CEPI) announced that it had partnered with Shanghai Zerun Biotechnology and its parent company, Walvax Biotech, to develop [[COVID-19 vaccines|COVID-19 vaccine]] candidates against both the original strain of [[SARS-CoV-2]] and its newer variants.((//CEPI partners with Shanghai Zerun Biotech to develop COVID-19 variant vaccine.// (2021, July 21). CEPI. https://web.archive.org/web/20220611060746/https://cepi.net/news_cepi/cepi-partners-with-shanghai-zerun-biotech-to-develop-covid-19-variant-vaccine/)) As of October 2022, CEPI had provided up to $25.1 million USD towards a candidate called 202-CoV, but had ceased further funding. The chimeric protein candidate remains in Phase I clinical trials.+In July 2021, the [[:Coalition for Epidemic Preparedness Innovations]] (CEPI) announced that it had partnered with Shanghai Zerun Biotechnology and its parent company, Walvax Biotech, to develop [[:COVID-19 vaccines|COVID-19 vaccine]] candidates against both the original strain of [[:SARS-CoV-2]] and its newer variants.((//CEPI partners with Shanghai Zerun Biotech to develop COVID-19 variant vaccine.// (2021, July 21). CEPI. https://web.archive.org/web/20220611060746/https://cepi.net/news_cepi/cepi-partners-with-shanghai-zerun-biotech-to-develop-covid-19-variant-vaccine/)) As of October 2022, CEPI had provided up to $25.1 million USD towards a candidate called 202-CoV, but had ceased further funding.((//Who we are.// CEPI. Retrieved October 19, 2022, from https://web.archive.org/web/20221019165747/https://cepi.net/about/whoweare/)) The chimeric protein candidate remains in Phase I clinical trials. 
 + 
 +===== External links ===== 
 + 
 +  * [[https://wiki.whiteroseintelligence.com/en/Shanghai-Zerun-Biotechnology|White Rose Wiki]]
Back to top